private-startup · consumer-wellness · consumer-sleep
Dreem
At a glance
- Legal name
- —
- Aliases
- Rythm
- Type
- private-startup
- Focus areas
- consumer-wellness, consumer-sleep, research-grade, data-platform
- Founded
- Defunct
- Spinout of
- —
- HQ city
- Paris
- HQ country
- FR
- Employees
- —
- Flagship device
- dreem-2
- Product lines
- 2
- In-house manufacturing
- —
- Open source
- —
- GitHub org
- —
- Website
- —
- Blog
- —
- Support
- —
Devices
People
Founders
Hugo Mercier
Co-Founder, CEO · departed
Quentin Soulet de Brugière
Co-Founder · departed
Current leadership
Pierrick Arnal
Chief Science Officer
Milestones
Rythm/Dreem founded in Paris
Dreem 1 launches
Dreem 2 launches
$35M Series B
Brings total raised to ~$60M; investors include Johnson & Johnson Innovation – JJDC, Bpifrance, MAIF Avenir.
Pivot to B2B / Dreem Health
Direct-to-consumer sales discontinued; company refocuses on healthcare, research, and clinical-trial sleep monitoring.
R&D business acquired by Beacon Biosignals
Beacon Biosignals acquires the R&D arm of Dreem, including the Dreem hardware platform and >2M nights of sleep data. The Dreem 3S goes on to receive FDA 510(k) clearance under Beacon.
Reputation
Treated as the most clinically-credible consumer sleep-EEG company of the 2010s — Dreem 2 was independently validated against polysomnography in SLEEP (2020). Consumer business never reached sustainable scale; the IP and 2M+ night dataset became Beacon Biosignals' Dreem 3S / Waveband platform.